Becton, Dickinson and Company (BD) has introduced the Surgiphor surgical wound irrigation system in Europe.
The system, which received CE approval, is currently available in select nations in the region.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is designed as a pre-mixed, sterile irrigation solution to assist with the removal of debris and foreign material from surgical wounds.
The solution is intended for application during procedures, eliminating the need for preparation by hospital staff.
It claims to incorporate a trusted antiseptic as a preservative to aid in decreasing bacterial load, which is linked to the risk of surgical site infections.
Additionally, BD Surgiphor features an easy-to-handle design that allows for quick and easy application by surgical teams.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBD Surgery worldwide president Rian Seger said: “This European launch marks a significant milestone in advancing surgical care.
“Surgical site infections are multifactorial and continue to present serious challenges to both patient outcomes and healthcare systems. Surgiphor supports clinicians in implementing evidence-based practices — such as surgical wound irrigation — to help reduce risk, enhance recovery, and improve overall surgical safety.”
According to BD, this launch demonstrates the company’s ongoing focus on progressing surgical care through practical solutions that prioritise patient safety.
In August 2025, the company announced an investment of over $35m to expand the manufacturing capacity of BD PosiFlush prefilled flush syringes at its Columbus, Nebraska facility in the US.
This expansion is expected to create 50 new jobs and increase production to meet growing demand from US health systems and hospitals.
Recently, BD obtained 510(k) clearance from the US Food and Drug Administration and CE marking under the European Union’s In Vitro Diagnostic Regulation for its bacterial panels for use on the BD COR System.
